NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis $2.89 +0.07 (+2.34%) Closing price 08/22/2025 03:19 PM EasternExtended Trading$2.91 +0.02 (+0.83%) As of 08/22/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xenetic Biosciences Stock (NASDAQ:XBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xenetic Biosciences alerts:Sign Up Key Stats Today's Range$2.72▼$3.1550-Day Range$2.74▼$4.1152-Week Range$2.20▼$5.27Volume20,458 shsAverage Volume32,887 shsMarket Capitalization$4.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More Xenetic Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreXBIO MarketRank™: Xenetic Biosciences scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Xenetic Biosciences.Read more about Xenetic Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xenetic Biosciences are expected to grow in the coming year, from ($1.01) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xenetic Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.49% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently increased by 32.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.49% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently increased by 32.93%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News SentimentN/A News SentimentXenetic Biosciences has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Xenetic Biosciences this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders14.70% of the stock of Xenetic Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.12% of the stock of Xenetic Biosciences is held by institutions.Read more about Xenetic Biosciences' insider trading history. Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIO Stock News HeadlinesXenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest UpdateAugust 20, 2025 | americanbankingnews.comHC Wainwright Issues Positive Estimate for XBIO EarningsAugust 17, 2025 | americanbankingnews.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 24 at 2:00 AM | Porter & Company (Ad)Xenetic Biosciences Reports Improved Financial PerformanceAugust 13, 2025 | msn.comXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the ...July 8, 2025 | finanznachrichten.deXenetic Biosciences (XBIO) Receives a Hold from H.C. WainwrightApril 9, 2025 | markets.businessinsider.comXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2025 | finance.yahoo.comXenetic Biosciences IncAugust 27, 2024 | money.usnews.comSee More Headlines XBIO Stock Analysis - Frequently Asked Questions How have XBIO shares performed this year? Xenetic Biosciences' stock was trading at $3.99 at the start of the year. Since then, XBIO stock has decreased by 27.7% and is now trading at $2.8860. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences, Inc. (NASDAQ:XBIO) released its earnings results on Tuesday, August, 12th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.19. The firm earned $0.59 million during the quarter, compared to analyst estimates of $0.48 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 54.56% and a negative net margin of 126.08%. When did Xenetic Biosciences' stock split? Shares of Xenetic Biosciences reverse split on the morning of Monday, May 15th 2023.The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Xenetic Biosciences' major shareholders? Xenetic Biosciences' top institutional shareholders include Sachetta LLC (0.99%). How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include FuelCell Energy (FCEL), OPKO Health (OPK), VBI Vaccines (VBIV), Bionano Genomics (BNGO), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). Company Calendar Last Earnings8/12/2025Today8/24/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XBIO CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Profitability EPS (Trailing Twelve Months)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.96 million Net Margins-126.08% Pretax Margin-126.04% Return on Equity-54.56% Return on Assets-47.28% Debt Debt-to-Equity RatioN/A Current Ratio5.93 Quick Ratio5.93 Sales & Book Value Annual Sales$2.50 million Price / Sales1.78 Cash FlowN/A Price / Cash FlowN/A Book Value$3.89 per share Price / Book0.74Miscellaneous Outstanding Shares1,540,000Free Float1,315,000Market Cap$4.44 million OptionableNot Optionable Beta2.31 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:XBIO) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.